Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474330 · ClinicalTrials.gov registry record · Phase 1
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01474330 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 33 participants.
The verdict
NCT01474330, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.
Interventions
- DRUG Placebo
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-08-01 |
| Est. Completion | 2011-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474330
The ClinicalTrials.gov registry entry for NCT01474330 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01474330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474330 about?
NCT01474330 is a clinical study titled "A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects". To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.
What is the current status of trial NCT01474330?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-08-01. Estimated completion is 2011-10-01.
What interventions are being tested in trial NCT01474330?
The interventions under investigation include: Placebo (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT01474330?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.